Analysts split on Amazon RxPass's impact on GoodRx Holdings
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/13/2026
- Nasdaq ends down as chipmakers fall and bank earnings roll in
- Oil prices settle mixed, focus on US-Russia diesel deal, Saudi Yemen attacks
- JPMorgan shares edge lower after third-quarter FICC revenue miss
- Fed’s Waller says US bond yield rise driven by growth, not inflation
- Wells Fargo beats profit estimates despite revenue miss
Citi Says Amazon (AMZN) RxPass 'Presents Credible Threat' to GoodRx Holdings Inc. (GDRX)
January 24, 2023 1:23 PM ESTCiti analyst Daniel Grosslight reiterated a Buy rating and $7.00 price target on GoodRx Holdings Inc. (NASDAQ: GDRX).
The analyst comments "AMZN announced today it is rolling out a new product, RXPass, which provides AMZNs 150-175M US Prime members with unlimited... More



